NT5E and head and neck squamous cell carcinoma: Clinical correlative data in recurrent/metastatic head and neck squamous cell carcinoma indicate that higher CD73 expression on neoplastic cells predicts inferior response to PD−1−based immunotherapy, prioritising CD73 inhibition or A2A receptor blockade as combination partners to restore effector function in adenosine−rich microenvironments (79, 80).